University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Talmadge King, M.D.


Dr. Talmadge E. King, Jr. is chair of the Department of Medicine at the University of California, San Francisco where he oversees a department of 1,372 doctors and scientists and more than 800 support staff. His focus in patient care is interstitial lung diseases, in particular idiopathic pulmonary fibrosis, sarcoidosis, connective tissue disease, hypersensitivity pneumonitis, drug-induced lung fibrosis and other rare diffuse lung disorders. King's research interests include pathogenesis, diagnosis and management of inflammatory and immunologic lung disease. He has co-authored eight books, including the acclaimed reference book, "Interstitial Lung Disease," now in its fifth edition.

King earned a medical degree at Harvard Medical School, followed by a residency at Emory University Affiliated Hospitals in Atlanta, Ga., and a pulmonary fellowship at the University of Colorado Health Sciences Center in Denver. He is a member of the Association of American Physicians, American Clinical and Climatological Association and Fleischner Society and is a fellow of the American College of Physicians and the American College of Chest Physicians. He holds the Julius R. Krevans Distinguished Professorship in Internal Medicine and won the 2007 Trudeau Medal, the highest honor of the American Lung Association and American Thoracic Society.


Interstitial Lung Disease Program
400 Parnassus Ave., Fifth Floor
San Francisco, CA 94143
Phone: (415) 353-2577
Fax: (415) 353-2568

Hours: Friday
8 a.m. – noon

Conditions & Treatments

More about Talmadge King


Harvard School of Medicine 1974


Emory University Affiliated Hospitals, Internal Medicine 1977


University of Colorado Medical Center, Pulmonary/Critical Care 1979

Selected Research and Publications

  1. Swigris JJ, Streiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Respir Med. 2014 Jan; 108(1):181-8.
  2. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013; 14:73.
  3. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013 Jul; 1(5):369-76.
  4. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013 Jun; 143(6):1699-708.
  5. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012 Jul 1; 186(1):88-95.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.